Asymmetric dimethylarginine in hemodialysis, hemodiafiltration, and peritoneal dialysis.

摘要: Asymmetric dimethylarginine (ADMA) is a mediator of endothelial dysfunction. Production and elimination ADMA may be affected by the type renal replacement therapy used oxidative stress. Plasma ADMA, advanced glycation end products (AGE), homocysteine were assessed in 59 subjects: 20 hemodialysis (HD) patients, 19 patients undergoing peritoneal dialysis (PD), controls. Results compared between groups. The effect 8 weeks HD high-volume predilution hemodiafiltration (HDF) was randomized study. showed higher (1.20 [0.90-1.39 micromol/L]) to controls (0.89 [0.77-0.98], P < 0.01), while PD did not differ from (0.96 [0.88-1.28]). AGE highest HD, lower (P 0.01 vs. HD), lowest 0.001 PD). had residual function than 0.01). decrease at (from 1.25 [0.97-1.33] 0.66 [0.57-0.73], 0.001) comparable that HDF. Switching HDF led predialysis level 0.05), change. Increased levels as PD, caused stress HD. Other factors, such diabetes statin therapy, also play. comparable. decreases without affecting ADMA.